TL;DR
- •Atypical antipsychotics are widely used in mood disorders — as augmentation for treatment-resistant depression, primary mood stabilization in bipolar disorder, or treatment of mixed episodes.
- •Common agents with FDA approvals in mood disorders: Abilify (depression augmentation, bipolar), Seroquel (bipolar depression, bipolar mania, depression augmentation), Latuda (bipolar depression), Vraylar (bipolar depression, mania, depression augmentation), Rexulti (depression augmentation).
- •Distinct from older antipsychotics ("typicals" like haloperidol) by acting on serotonin receptors in addition to dopamine — broader profile, fewer motor side effects, but with new side effect concerns.
- •Metabolic side effects (weight gain, blood sugar, lipids) are the main concern with long-term use. Seroquel and olanzapine are highest-risk; Abilify and Latuda are most metabolically neutral.
- •For bipolar depression specifically, atypicals are FIRST-line (not SSRIs alone, which can destabilize). The bipolar screening before any antidepressant is exactly why the MDQ exists.
- •For unipolar treatment-resistant depression where SSRI + atypical augmentation has not produced sufficient response, ketamine offers a different mechanism with rapid action.
How this class works
Atypical antipsychotics block dopamine D2 receptors (the original antipsychotic action) plus serotonin 5-HT2A receptors and varying combinations of other receptors depending on the specific agent. The serotonin effect plus partial dopamine agonism (some agents like Abilify, Vraylar, Rexulti) produces mood-stabilizing and augmentation properties beyond what older "typical" antipsychotics could achieve. The trade-off is metabolic side effects from receptor activity in non-CNS tissues.
Medications in this class
Tovani has detailed drug-interaction pages for 2 atypical antipsychotics. Click any to see the ketamine-interaction verdict, mechanism, and FAQ.
Why patients look for alternatives
- •Weight gain, often substantial (10+ lbs over months for higher-risk agents)
- •Metabolic syndrome — elevated blood sugar, triglycerides, blood pressure
- •Sedation (particularly Seroquel, less for newer agents)
- •Akathisia (motor restlessness, inner agitation) — often described as worse than depression itself
- •Cost — many atypicals are still brand-name and expensive
- •Stigma around "antipsychotic" label even when prescribed for depression or mood
Where ketamine fits
Clinical indication
For treatment-resistant unipolar depression where SSRI plus atypical-antipsychotic augmentation has not produced sufficient response, ketamine's NMDA/glutamate mechanism is a different path with rapid onset. For bipolar depression on atypical maintenance, ketamine can be considered alongside the mood stabilizer with specific protocols.
Onset comparison
Hours vs days-to-weeks. Atypicals as augmentation typically take 2-4 weeks to add measurable effect to existing SSRI; sublingual ketamine produces measurable response within hours of the first session.
Contraindications and coordination
Active bipolar disorder without mood stabilizer coverage is a relative contraindication for ketamine — bipolar patients should remain on their atypical antipsychotic or mood stabilizer during ketamine treatment to prevent mood elevation. Standard contraindications apply: uncontrolled hypertension, active substance use disorder, severe cardiovascular disease, active psychotic disorder, pregnancy/breastfeeding.
5-minute screening · Reviewed by a board-certified physician · FL & NJ
Other alternatives worth knowing about
Ketamine isn’t the only escalation path. These are the other options your physician may consider, depending on your history.
Lithium augmentation
Adding lithium to existing antidepressant is well-established for treatment-resistant depression. Cheaper than atypicals but requires blood monitoring (kidney, thyroid).
Thyroid (T3) augmentation
Liothyronine (Cytomel) addition to SSRI has decades of evidence as a depression augmentation strategy. Generally well-tolerated.
Switch atypical agent
Within-class switch — e.g., Seroquel to Latuda for metabolic concerns, or Abilify to Rexulti for akathisia. Doesn't change the mechanism class but addresses specific side-effect concerns.
TMS for unipolar treatment-resistant depression
Non-pharmacological option that avoids the metabolic, sedation, and motor side effects of atypicals. Daily clinic visits for 6 weeks.
Frequently asked
Why is my doctor adding an antipsychotic when I have depression, not psychosis?
Several atypical antipsychotics are FDA-approved as ADD-ON treatment for depression (Abilify, Rexulti, Vraylar, Seroquel) — they augment the antidepressant effect of an existing SSRI/SNRI. The "antipsychotic" label is historical and can be confusing; many clinicians and patients are pushing for renaming these agents. The mechanism (partial dopamine modulation plus serotonin effects) is genuinely useful in depression, separate from any psychotic-symptom indication.
Will I gain a lot of weight on an atypical?
Depends on the agent. Highest-risk: Zyprexa (olanzapine), Seroquel (quetiapine). Moderate: Risperdal, Vraylar, Rexulti. Lowest: Abilify (aripiprazole), Latuda (lurasidone), Geodon. If weight matters, your prescriber can typically choose a more metabolically neutral option. Annual labs (fasting glucose, lipids) are standard.
What is akathisia?
Motor restlessness combined with inner agitation — patients often describe it as "wanting to crawl out of my skin." Common with atypicals, particularly Abilify. Treatable (propranolol, benzodiazepines short-term, dose reduction, switch agent). Patients should report it early because it gets worse over time if untreated.
Can ketamine replace my Abilify/Seroquel?
For unipolar depression on atypical augmentation, ketamine response often allows dose reduction or discontinuation of the augmenting agent — but the timing and approach depends on the original indication. For bipolar disorder, the mood stabilizer typically stays during ketamine treatment to prevent mood elevation. This is a coordinated medication change with your prescriber.
My SSRI plus Abilify isn't enough. What's next?
You meet treatment-resistant depression criteria after one failed antidepressant trial plus one failed augmentation. Options: switch the atypical (different agent), switch the antidepressant class, add lithium or thyroid, TMS, or ketamine. Ketamine has the strongest evidence in the treatment-resistant subset and acts on a completely different mechanism.
References
- Murrough JW et al. 2013, American Journal of Psychiatry. Ketamine RCT in treatment-resistant depression — relevant for patients who had failed prior SSRI plus atypical-antipsychotic augmentation strategies. PMID 23982301
- Sanacora G et al. 2017, JAMA Psychiatry. APA consensus on ketamine in mood disorders — explicitly addresses use in bipolar depression and considerations for patients on atypical antipsychotic background therapy. PMID 28249076